Boston Scientific is initiating a global restructuring programme in an effort to drive “sustained cost efficiencies” and support continued growth that it concedes will also result in job cuts across the business.
The 2026 restructuring plan will span supply chain optimisation, including transferring certain production lines among facilities, targeted functional transformation and organisational “structure evolution” to drive sustained cost efficiencies, Boston stated, with these activities expected to be largely finished by the end of 2029.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Agreed with Boston’s board on 21 July and publicly disclosed in a Form 8-K filing with the US Securities and Exchange Commission (SEC) on 27 July, the medtech giant anticipates that the plan will cost between $700m and $800m, of which approximately $600m to $700m is expected to result in future cash outlays, as well as reducing annual pre-tax expenses by approximately $500m as the programme’s benefits are realised.
Boston’s shares on the New York Stock Exchange (NYSE) rose by 2.85% to $45.51 at market close on 27 July, up from $44.60 at market open. Boston has a market cap of $67.64bn. Shares rose by a further 2% at market open on 28 July.
Boston disclosed that while the plan will result in new jobs being created to support its portfolio and global market needs, it also expects “some” headcount reductions as a result of these restructuring activities.
While no specific numbers were provided regarding headcount reductions, in a costing breakdown contained in Boston’s Form 8-K, the company estimated that up to $300m will be incurred due to terminations. Meanwhile, up to $350m of the total cost will relate to transferring product manufacturing lines between geographically dispersed facilities, and up to $150m for ‘other’ costs associated with the plan’s completion.
Boston is set to release its Q2 results on 29 July. In Q1, the company reported revenue of around $5.2bn, broadly in line with the same quarter in 2025. However, Boston elected to trim its full-year outlook by 2% at the top end, with CEO Mike Mahoney citing “ongoing competitive dynamics”.
